Harrow Completes $50M Senior Notes Offering to Fund Growth Initiatives
Summary
Harrow, Inc. completed a $50 million private offering of 8.625% Senior Notes due 2030, securing approximately $48.7 million in net proceeds to fund growth initiatives and product development.
Key Events
-
Completion of $50 Million Senior Notes Offering
Harrow, Inc. completed a private offering of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 on March 27, 2026.
-
Net Proceeds for Growth and Product Development
The company received approximately $48.7 million in net proceeds, which will be used for general corporate purposes, including funding growth initiatives, product development, and strategic business opportunities.
-
Integration with Existing Debt Structure
These new notes are issued under the same indenture as the $250 million of 8.625% Senior Notes due 2030 issued on September 12, 2025, bringing the total outstanding amount to $300 million.
Analysis
Harrow, Inc. has completed a private offering of $50.0 million in additional 8.625% Senior Notes due 2030, finalizing the terms of the offering initiated on March 24, 2026. The company received net proceeds of approximately $48.7 million after deducting discounts and estimated offering expenses. These proceeds are earmarked for general corporate purposes, including accelerating growth initiatives, funding product development, and pursuing strategic business development opportunities. This capital raise is substantial for the company, providing significant liquidity to support its strategic objectives, though it adds to the existing debt structure, which now totals $300 million in these notes.
At the time of this filing, HROW was trading at $33.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $20.85 to $54.85. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.